FIGURE 2.

Aβ_arc flies climbing assay. Aβ_arc flies climbing assay under different treatments. Data show the climbing performance trends over a 21-day period. Data generated from the climbing index was processed as a percentage of the total. In order to compare vials with a different number of flies, repeated measures analysis of variance was used to compare climbing scores between treated and untreated groups. (A) Climbing assay of untreated Aβ_arc flies. (B) Climbing assay of Aβ_arc flies treated with XJP-1. (C) Climbing assay of Aβ_arc flies treated with donepezil. (D) Climbing assay of Aβ_arc flies treated with rivastigmine. (E) Climbing assay of Aβ_arc flies treated with galantamine. (F) Climbing assay of Aβ_arc flies treated with memantine. (G) Climbing assay of Aβ_arc flies treated with XJP-1 and memantine. (H) Climbing assay of Aβ_arc flies treated with donepezil and memantine. Data are presented in the figure as the mean ± SD; data are compared against the untreated group. n = 3 (number of independent experiments, each experiment with a minimum of 10 flies per treatment). P < 0.05 was considered as significant. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.